Beam Therapeutics: 여전히 상승 여력이 남아있는 밸류에이션 (NASDAQ:BEAM)
· seekingalpha.com
Beam Therapeutics (BEAM) 주식 전망: 유전자 교정 파이프라인, 2029년까지 확보된 강력한 현금 활주로, 그리고 보수적인 밸류에이션.
Max is an independent equity research analyst with a primary focus on biotechnology, healthcare, and technology companies. His investment approach is fundamenta...